<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Thirty-five patients, 24 males and 11 females, with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> were studied for the expression of c-myc encoded p67 oncoprotein </plain></SENT>
<SENT sid="1" pm="."><plain>According to FAB classification, 5 patients had refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> (RA) </plain></SENT>
<SENT sid="2" pm="."><plain>5 refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> with ringed sideroblasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>), 17 refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> with excess of blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>), 4 refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> with excess of blasts in transformation (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t), and 4 <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_501'>myelomonocytic leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>The mouse anti-human 9E10 derived monoclonal antibody in the standard APAAP technique for immunohistochemical analysis was used </plain></SENT>
<SENT sid="4" pm="."><plain>A scoring method similar to that routinely used for endogenous neutrophil alkaline phosphatase estimation, was applied to obtain parametrically comparable results </plain></SENT>
<SENT sid="5" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo> but two <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients, the observed c-myc oncoprotein score values did not differ statistically from those found in the controls </plain></SENT>
<SENT sid="6" pm="."><plain>The values did not correlate with peripheral blood or bone marrow blast cell numbers </plain></SENT>
<SENT sid="7" pm="."><plain>In two out of 17 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in whom very high c-myc score values were found, <z:hpo ids='HP_0011009'>acute</z:hpo> non-lymphocytic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (ANLL) was diagnosed 30 and 45 days later, respectively </plain></SENT>
<SENT sid="8" pm="."><plain>Furthermore, we found high c-myc score values in three patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> and in two patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t during the ANLL phase which was diagnosed six to ten months after the initial study </plain></SENT>
<SENT sid="9" pm="."><plain>Our data suggest that c-myc activation may be seen in <z:hpo ids='HP_0000001'>all</z:hpo> cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> in overt ANLL phase, and also in some <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> patients a few weeks before diagnosis of overt ANLL </plain></SENT>
<SENT sid="10" pm="."><plain>The possible prognostic value of c-myc activation in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients remains to be clarified </plain></SENT>
</text></document>